Exact Therapeutics AS (EXTX.OL)
Oslo · NOK · Healthcare · Biotechnology
NOK 0.70 (+0.00%) as of
Key statistics
- Market cap
- 78.08M
- EPS (TTM)
- -0.9300
- Dividend yield
- 0.00%
- 52-week range
- 0.4260 – 2.7000
- Beta
- 0.11
- Revenue (TTM)
- 78k
- Profit margin
- 0.00%
- Volume
- 400.46k
About Exact Therapeutics AS
EXACT Therapeutics AS, a clinical stage biopharmaceutical company, develops a novel ultrasound-mediated technology platform for targeted therapeutic enhancement, Acoustic Cluster Therapy (ACT) in Norway. The ACT is an approach to ultrasound-mediated, targeted drug enhancement with the potential to amplify the clinical utility of a range of therapeutic agents across various applications, including oncology, neurological conditions, and gene therapy. The company's ACT platform is under Phase 2 clinical trial for the treatment of pancreatic disease; Phase I clinical trial for treatment of liver metastases; and pre-clinical studies for glioblastoma, and immunotherapy diseases, as well as CNS diseases and gene therapy. It has a collaboration with GE Healthcare. The company was formerly known as Phoenix Solutions AS. EXACT Therapeutics AS was founded in 2012 and is based in Oslo, Norway.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Oslo, Norway
- Employees
- 11
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.